Table 5:
Cox regression analyses for overall survival and recurrence-free survival/progression-free survival
| HR | 95% CI | P-Value | ||
|---|---|---|---|---|
| OS | ||||
| Histological subtype (reference = thymoma) | 6.77 | 1.95 | 23.46 | 0.003 |
| Additive chemotherapy (reference = no) | 0.52 | 0.13 | 2.02 | 0.344 |
| RFS/PFSa | ||||
| Cisplatin dosage (reference = low dosage) | 0.64 | 0.22 | 1.85 | 0.409 |
| Chemotherapeutical agent (reference = cisplatin) | 2.02 | 0.71 | 5.70 | 0.186 |
| Resection status (reference = R0/1) | 0.79 | 0.30 | 2.12 | 0.640 |
| Histological subtype (reference = thymoma) | 3.34 | 1.39 | 8.02 | 0.007 |
| Additive chemotherapy (reference = no) | 2.11 | 0.93 | 4.76 | 0.073 |
In the Cox regression analyses, 1 patient was excluded due to atypical carcinoid of the thymus. Moreover, a limitation of number of parameters in the multivariable analyses were necessary, only variables with P-values <0.1 in univariable analyses were included in the Cox regression.
a
The covariate time between initial diagnosis and beginning of primary therapy was included the statistical model.
CI: confidence interval; HR: hazard ratio; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival.
Bold represents Statistical significant.